Results 41 to 50 of about 5,276 (141)

Cefepime exposure in prolonged or intermittent infusion in critically ill children

British Journal of Clinical Pharmacology, EarlyView.
Aims Cefepime is commonly used in critically ill children for whom there is a high between‐subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, prolonged infusion of beta‐lactams seems to be the most efficient.
Marc Hobeika, Deborah Hirt, Emmanuelle Bille, Sihem Benaboud, Julie Toubiana, Pierre‐Louis Léger, Jérôme Rambaud, Agathe Béranger, Delphine Callot, Sylvain Renolleau, Jean‐Marc Treluyer, Mehdi Oualha, Noémie de Cacqueray   +12 more
wiley   +1 more source

EUCAST-Neudefinition der Kategorie „I“ – zum Umgang hinsichtlich der Meldepflicht [PDF]

, 2019
Das European Committee on Antimicrobial Susceptibility Testing (EUCAST) hat die Kategorie "I" bei der Antibiotika-Resistenz­bestimmung neu definiert. Demnach berücksichtigen die Bewertungen "S" und "I" ab dem 1.1.2019 mit Inkrafttreten der neuen EUCAST ...
Robert Koch-Institut
core   +1 more source

Successful Translational Prediction of Bedaquiline's Phase 2a Clinical Trial Results against Tuberculosis: The Zebrafish as a New Approach Methodology

Clinical Pharmacology &Therapeutics, EarlyView.
Tuberculosis remains an urgent global health crisis that requires an accelerated development of novel regimens. Rodent and rabbit studies currently inform early translational predictions. However, the zebrafish (Danio rerio) embryo/larva, as a New Approach Methodology, provides an ethical, cost‐effective, and high‐throughput non‐mammalian disease model
Bart van Lieshout, Aanisah Hanuun, J. G. Coen van Hasselt, Rob C. van Wijk   +3 more
wiley   +1 more source

EUCAST expert rules in antimicrobial susceptibility testing

, 2011
EUCAST expert rules have been developed to assist clinical microbiologists and describe actions to be taken in response to specific antimicrobial susceptibility test results.
BROWN D. F., HEISIG P., RODLOFF A. C., ROSSOLINI G. M., WINSTANLEY T. G., MOUTON J. W., STEINBAKK M., GISKE C. G., SOUSSY C. J., CANTON R., MACGOWAN A. P., NORDMANN P., LECLERCQ R., KAHLMETER G.   +13 more
core   +1 more source

Challenges for interpreting results of antimicrobial susceptibility testing for treating infections of foals with Rhodococcus equi

Equine Veterinary Journal, EarlyView.
Abstract Rhodococcus equi is a facultative intracellular pathogen and a major cause of pneumonia in foals worldwide. The standard treatment for affected foals is a combination of a macrolide with rifampicin. The widespread use of this combination has led to the emergence of multidrug‐resistant (MDR) strains of R. equi.
Marlane Geribone Seeger, Letícia Trevisan Gressler, Laura Huber, Sonsiray Alvarez‐Narvaez, Juliana Felipetto Cargnelutti, Angela Ilha Bordin, Sara D. Lawhon, Noah D. Cohen   +7 more
wiley   +1 more source

In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020

Journal of Global Antimicrobial Resistance, 2023
: Objectives: To evaluate eravacycline (ERV) activity against Gram-negative and Gram-positive bacteria collected between 2017 and 2020 from worldwide locations. Methods: MIC determinations were performed using Clinical and Laboratory Standards Institute
Stephen Hawser, Nimmi Kothari, Federica Monti, Ian Morrissey, Sherry Siegert, Tony Hodges   +5 more
doaj   +1 more source

Antimicrobial Sensitivity Profile and Resistance Gene Research in Escherichia coli Isolated From Water and Fish From Lagoa da Conceição, Florianópolis, SC, Brazil

Food Safety and Health, EarlyView.
This paper highlights a concerning scenario of environmental contamination by multidrug‐resistant bacteria, underscoring the need for integrated surveillance and control strategies to address antimicrobial resistance in aquatic environments within the context of One Health.
Francisco Lucas de Amorim Nascimento, Luan Amaral Alexandre, Cynthia Farias Manassi, Alice Cristina da Silva, Luísa Aimée Schmitt Lobe, Gustavo Rocha, Mateus Rocha Ribas, Victor Wolleck, Gabriele Caroline Gottschalk de Abreu, Alessandra Valéria Vortmann, Sheila Mello da Silveira, Rodrigo Barcellos Hoff, Jussara Kasuko Palmeiro, Silvani Verruck   +13 more
wiley   +1 more source

In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies

Journal of Fungi, 2021
Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of Aspergillus
Olga Rivero-Menendez, Juan Carlos Soto-Debran, Manuel Cuenca-Estrella, Ana Alastruey-Izquierdo   +3 more
doaj   +1 more source

The Preparation of Novel Fluorenes Inspired by Hipposudoric Acid

Helvetica Chimica Acta, EarlyView.
In this research we report on the design and synthesis of a series of fluorene‐based derivatives loosely inspired by the tricyclic framework of hipposudoric acid. Preparation of sixteen novel N‐alkylated derivatives was accomplished via a series of concise one‐step amide N‐alkylation reactions.
Munib Uddin, Freya Harrison, Florida Koçi, Stephen P. Wren   +3 more
wiley   +1 more source

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance. [PDF]

, 2019
We investigated the impact of breakpoint discrepancies between CLSI and EUCAST on susceptibility interpretation of clinical isolates at the Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos and performed a literature search to compare our ...
Dance, DAB, Turner, Paul, Cusack, TP, Wangrangsimakul, Tri, Roberts, T, Ashley, Elizabeth, Rattanavong, S, Cusack, T-P, Wangrangsimakul, T, Ashley, EA, Ling, CL, Turner, P   +11 more
core   +1 more source